logo

Trevena, Inc. (TRVN)



Trade TRVN now with
  Date
  Headline
9/30/2021 7:37:01 AM Trevena Announces Results Of TRV027 Proof-of-Concept Study In COVID-19 Patients
7/8/2021 7:24:36 AM Trevena Enrolls First Patient Enrolled In OLINVYK Phase 3 Trial In China In Partnership With Jiangsu Nhwa Pharma
12/1/2016 10:49:48 AM Wedbush Reiterates Trevena, Inc. (TRVN) At Outperform With $16 Price Target
11/3/2016 9:37:46 AM Wedbush Is Cutting Trevena, Inc. (TRVN) Q4 17 Estimate To -0.54 From -0.45
11/3/2016 9:37:33 AM Wedbush Is Cutting Trevena, Inc. (TRVN) Q3 17 Estimate To -0.50 From -0.40
11/3/2016 9:37:21 AM Wedbush Is Lowering Trevena, Inc. (TRVN) Q2 17 Estimate To -0.54 From -0.44
11/3/2016 9:37:07 AM Wedbush Is Lowering Trevena, Inc. (TRVN) Q1 17 Estimate To -0.56 From -0.45
11/3/2016 9:36:10 AM Wedbush Is Lowering Trevena, Inc. (TRVN) 2017 Estimate To -2.14 From -1.74
11/3/2016 9:35:52 AM Wedbush Is Lowering Trevena, Inc. (TRVN) 2016 Estimate To -1.88 From -1.60
11/3/2016 9:35:37 AM Wedbush Is Cutting Trevena, Inc. (TRVN) Q4 16 Estimate To -0.60 From -0.45
11/3/2016 9:34:53 AM Wedbush Is Cutting Trevena, Inc. (TRVN) Q3 16 Estimate To -0.57 From -0.43
11/3/2016 9:31:46 AM Wedbush Reiterates Trevena, Inc. (TRVN) At Outperform With $16 Price Target
10/26/2016 11:47:08 AM Wedbush Reiterates Trevena, Inc. (TRVN) At Outperform With $16 Price Target
8/4/2016 12:32:46 PM Wedbush Is Increasing Trevena, Inc. (TRVN) 2017 Estimate To -1.74 From -2.16
8/4/2016 12:32:27 PM Wedbush Is Increasing Trevena, Inc. (TRVN) 2016 Estimate To -1.60 From -1.69
5/16/2016 10:06:41 AM Wedbush Reiterates Trevena, Inc. (TRVN) At Outperform With $16 Down From $20 Price Target
5/5/2016 3:57:29 PM Wedbush Is Cutting Trevena, Inc. (TRVN) FY 16 Estimate To -1.69 From -1.26